Nexalin Technology Inc 's ability to collect accounts receivable sequentially worsen to 4.07, indicating more challenging environment then in the first quarter 2026, but still, it is a far cry from any concerns. Nexalin Technology Inc 's Accounts Receivable average collection period in the Jun 30 2026 quarter, has increased to 90 days, from 64 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 505 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 2729 to 3378.

What is Receivable Turnover Ratio?
What is Nexalin Technology Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NXL Receivables Turnover Ratio	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Receivable Change	35.36 %	197.01 %	525.4 %	-47.76 %	410.59 %
Y / Y Revenue Change	-82.77 %	-63.55 %	532.46 %	-49.63 %	163 %
Receivable Turnover Ratio (TTM)	4.07	5.73	7.37	6.59	6.82
NXL's Total Ranking	# 3378	# 2729	# 2959	# 3121	# 1702
Accounts Receivable average collection period days	90	64	50	55	54
Seq. Receivable Change	88.35 %	-47.28 %	929.29 %	-86.76 %	313.3 %
Seq. Revenue Change	-18.66 %	-91.3 %	847.13 %	-74.29 %	72.1 %

Receivable Turnover Company Ranking
Within:	No.
Medical Equipment & Supplies Industry	# 171
Healthcare Sector	# 506
Overall Market	# 3378

Receivable Turnover Ratio Statistics
High	Average	Low
0.18	0.06	0.02
(Mar 31 2023)		(Sep 30 2023)

NXL Company Profile • Back to NXL Efficiency Comparisons • Compare NXL Receivables Turnover Ratio to its Competitors

Financial Statements
Nexalin Technology Inc 's Accounts Receivable	$ 0 Millions	Visit NXL's Balance sheet
Nexalin Technology Inc 's Sales TTM	$ 0 Millions	Visit NXL's Income Statement
Sources of NXL's Revenues		Visit NXL's Sales by Geography

Other Accounts Receivable Turnover Ratios
Medical Equipment & Supplies Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
NXL's Receivable Turnover Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
NXL's Growth Rates	NXL's Roa	NXL's Inventory Turnover Ratio	NXL's Dividend Comparisons
NXL's Profitability Ratios	NXL's Roi	NXL's Asset Turnover Ratio	NXL's Dividend Growth
NXL's Valuation Ratios	NXL's Roe	NXL's Financial Strength Ratios	NXL's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Lucid Diagnostics Inc	7.33	$ 5.445 Millions	$ 0.742 Millions
Foxo Technologies Inc	7.27	$ 24.846 Millions	$ 3.420 Millions
Si bone inc	7.23	$ 214.331 Millions	$ 29.648 Millions
Safe Pro Group Inc	7.23	$ 2.881 Millions	$ 0.399 Millions
Insmed Inc	7.18	$ 1,076.572 Millions	$ 149.999 Millions
Rhythm Pharmaceuticals Inc	7.18	$ 239.918 Millions	$ 33.429 Millions
Twist Bioscience Corporation	7.10	$ 431.798 Millions	$ 60.812 Millions
Boston Scientific Corporation	7.10	$ 20,997.000 Millions	$ 2,957.500 Millions
Travere Therapeutics Inc	7.10	$ 591.330 Millions	$ 83.339 Millions
Angiodynamics Inc	7.08	$ 317.726 Millions	$ 44.853 Millions
Pulmonx Corporation	7.07	$ 87.393 Millions	$ 12.356 Millions
Arcturus Therapeutics Holdings Inc	7.05	$ 29.368 Millions	$ 4.168 Millions
Tandem Diabetes Care Inc	6.98	$ 1,037.302 Millions	$ 148.542 Millions
Sutro Biopharma Inc	6.98	$ 45.702 Millions	$ 6.545 Millions
Edwards Lifesciences Corporation	6.98	$ 6,512.500 Millions	$ 933.400 Millions
Beyond Air Inc	6.98	$ 6.677 Millions	$ 0.957 Millions
Quidelortho Corp	6.92	$ 2,674.200 Millions	$ 386.400 Millions
Myriad Genetics Inc	6.91	$ 805.900 Millions	$ 116.650 Millions
Ceribell Inc	6.90	$ 101.804 Millions	$ 14.749 Millions
Stryker Corp	6.89	$ 25,837.000 Millions	$ 3,749.000 Millions
Nephros Inc	6.83	$ 21.686 Millions	$ 3.173 Millions
Medpace Holdings Inc	6.82	$ 2,782.288 Millions	$ 408.189 Millions
Opko Health Inc	6.79	$ 587.896 Millions	$ 86.589 Millions
Atara Biotherapeutics Inc	6.79	$ 6.452 Millions	$ 0.950 Millions
Rapid Micro Biosystems Inc	6.76	$ 34.545 Millions	$ 5.111 Millions
Universal Health Services Inc	6.75	$ 18,114.487 Millions	$ 2,683.492 Millions
Delcath Systems Inc	6.73	$ 94.058 Millions	$ 13.981 Millions
3m Company	6.72	$ 25,180.000 Millions	$ 3,747.750 Millions
Phibro Animal Health Corporation	6.70	$ 1,516.861 Millions	$ 226.555 Millions
Envista Holdings Corporation	6.69	$ 2,856.400 Millions	$ 427.250 Millions

Date modified: 2026-09-12T06:26:46+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.